Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol

ISRCTN ISRCTN77942127
DOI https://doi.org/10.1186/ISRCTN77942127
Secondary identifying numbers N/A
Submission date
08/09/2005
Registration date
27/10/2005
Last edited
11/10/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Matthew Walters
Scientific

Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom

Phone +44 (0)141 211 2821
Email gcl203@clinmed.gla.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleReversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol
Study objectivesTo investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension.
Ethics approval(s)West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1)
Health condition(s) or problem(s) studiedHypertension
InterventionPatients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Losartan, atenolol
Primary outcome measureChanges in cerebrovascular reactivity.
Secondary outcome measuresNot provided at time of registration
Overall study start date01/08/2004
Completion date01/02/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexMale
Target number of participants13
Key inclusion criteria1. Male: 50-80 years
2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH)
3. Blood pressure (BP) 150-200/90-115
Key exclusion criteria1. >70% internal carotid artery (ICA) stenosis
2. Middle cerebral artery (MCA) stenosis
3. Contra-indication to losartan, atenolol or acetazolamide
4. Serum creatinine >130 µmol/l
5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment
Date of first enrolment01/08/2004
Date of final enrolment01/02/2006

Locations

Countries of recruitment

  • Scotland
  • United Kingdom

Study participating centre

Western Infirmary
Glasgow
G11 6NT
United Kingdom

Sponsor information

University of Glasgow (UK)
University/education

University Avenue
Glasgow
G11 6NT
Scotland
United Kingdom

Phone +44 (0)141 211 2176
Email pcn1w@clinmed.gla.ac.uk
ROR logo "ROR" https://ror.org/00vtgdb53

Funders

Funder type

University/education

University of Glasgow
Private sector organisation / Universities (academic only)
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

11/10/2016: No publications found, verifying study status with principal investigator.